Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.29)
# 430
Out of 4,412 analysts
47
Total ratings
47.5%
Success rate
19.94%
Average return
Main Sectors:
Top Industries:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Hold | $91 → $89 | $82.13 | +8.36% | 5 | Apr 26, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sell | $371 | $396.20 | -6.36% | 5 | Apr 12, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Buy | $7 | $2.45 | +185.71% | 6 | Mar 21, 2024 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $19 → $18 | $4.54 | +296.48% | 3 | Mar 20, 2024 | |
| RGLS Regulus Therapeutics | Maintains: Buy | $12 → $11 | $2.52 | +336.51% | 3 | Mar 19, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $81 → $87 | $26.63 | +226.70% | 3 | Mar 11, 2024 | |
| PASG Passage Bio | Reiterates: Buy | $14 | $1.30 | +976.92% | 2 | Mar 5, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $72 → $73 | $21.98 | +232.12% | 3 | Feb 23, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $110 → $111 | $44.02 | +152.16% | 2 | Feb 21, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $49 → $47 | $21.85 | +115.10% | 2 | Aug 11, 2023 | |
| VERV Verve Therapeutics | Reiterates: Buy | $29 | $6.26 | +363.26% | 2 | Jun 16, 2023 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $52 → $56 | $38.82 | +44.26% | 2 | Mar 2, 2023 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $310 → $291 | $147.36 | +97.48% | 2 | Feb 24, 2023 | |
| GBIO Generation Bio Co. | Initiates: Buy | $9 | $2.85 | +215.79% | 1 | Nov 8, 2022 | |
| SRPT Sarepta Therapeutics | Upgrades: Buy | n/a | $128.80 | - | 1 | Sep 15, 2021 | |
| NBSE NeuBase Therapeutics | Initiates: Buy | n/a | $0.42 | - | 1 | Feb 7, 2020 | |
| GILD Gilead Sciences | Downgrades: Neutral | n/a | $65.94 | - | 1 | Jan 21, 2020 | |
| KPTI Karyopharm Therapeutics | Downgrades: Neutral | n/a | $1.10 | - | 3 | Mar 1, 2019 |
BioMarin Pharmaceutical
Apr 26, 2024
Maintains: Hold
Price Target: $91 → $89
Current: $82.13
Upside: +8.36%
Vertex Pharmaceuticals
Apr 12, 2024
Maintains: Sell
Price Target: $371
Current: $396.20
Upside: -6.36%
Taysha Gene Therapies
Mar 21, 2024
Reiterates: Buy
Price Target: $7
Current: $2.45
Upside: +185.71%
Tenaya Therapeutics
Mar 20, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $4.54
Upside: +296.48%
Regulus Therapeutics
Mar 19, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $2.52
Upside: +336.51%
Arcturus Therapeutics Holdings
Mar 11, 2024
Maintains: Buy
Price Target: $81 → $87
Current: $26.63
Upside: +226.70%
Passage Bio
Mar 5, 2024
Reiterates: Buy
Price Target: $14
Current: $1.30
Upside: +976.92%
Intellia Therapeutics
Feb 23, 2024
Maintains: Buy
Price Target: $72 → $73
Current: $21.98
Upside: +232.12%
Ultragenyx Pharmaceutical
Feb 21, 2024
Maintains: Buy
Price Target: $110 → $111
Current: $44.02
Upside: +152.16%
Rocket Pharmaceuticals
Aug 11, 2023
Maintains: Buy
Price Target: $49 → $47
Current: $21.85
Upside: +115.10%
Verve Therapeutics
Jun 16, 2023
Reiterates: Buy
Price Target: $29
Current: $6.26
Upside: +363.26%
Rhythm Pharmaceuticals
Mar 2, 2023
Maintains: Buy
Price Target: $52 → $56
Current: $38.82
Upside: +44.26%
Alnylam Pharmaceuticals
Feb 24, 2023
Maintains: Buy
Price Target: $310 → $291
Current: $147.36
Upside: +97.48%
Generation Bio Co.
Nov 8, 2022
Initiates: Buy
Price Target: $9
Current: $2.85
Upside: +215.79%
Sarepta Therapeutics
Sep 15, 2021
Upgrades: Buy
Price Target: n/a
Current: $128.80
Upside: -
NeuBase Therapeutics
Feb 7, 2020
Initiates: Buy
Price Target: n/a
Current: $0.42
Upside: -
Gilead Sciences
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $65.94
Upside: -
Karyopharm Therapeutics
Mar 1, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.10
Upside: -